STUDY PROTOCOL article
Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1602666
This article is part of the Research TopicClinical Trials in Cardiovascular Medicine: 2025View all articles
Protocol for a randomized controlled trial of Xueshuantong Injection on myocardial injury and residual cardiovascular risk in patients with unstable angina
Provisionally accepted
- 1Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 2Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
- 3Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing Municipality, China
- 4Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Unstable angina (UA) is a critical subtype of acute coronary syndrome (ACS). Myocardial injury is a key determinant of disease progression and long-term prognosis, yet it often persists despite standard therapy. In addition, residual inflammation remains an important risk factor for adverse outcomes. Xueshuantong Injection Lyophilized (XST), derived from Panax notoginseng saponins (PNS), has shown potential to reduce myocardial injury and modulate inflammatory responses in cardiovascular disease, but its efficacy in UA has not been fully evaluated. Methods: This is a randomized, parallel control, double-blind, small-sample exploratory clinical trail. Participants will be recruited from Xiyuan Hospital, China Academy of Chinese Medical Sciences (Beijing, China). Eligible patients with UA will be randomized into two groups. The intervention group will receive XST 500 mg intravenously once daily for 7 days, and the control group will receive XST 25 mg intravenously once daily for 7 days. The primary outcome is CK-MB at Day 7. Secondary outcomes are cTnT, NT-proBNP, inflammatory/endothelial biomarkers (hs-CRP, IL-6, MMP-9, VEGF, HMGB1), and angina-related parameters (attack frequency, symptom severity). Ethics and Registration: The trial has been approved by the Ethics Committee of Xiyuan Hospital and registered in the ITMCTR on March 21, 2025, http://itmctr.ccebtcm.org.cn (No. ITMCTR2025000552). Conclusion: This exploratory study will evaluate the efficacy and safety of XST in reducing myocardial injury and residual risk in UA patients, providing evidence for future large-scale confirmatory trials.
Keywords: unstableangina, myocardialinjury, Cardiovascularrisk, Xueshuantong for injection, Randomized controlled trail
Received: 30 Mar 2025; Accepted: 30 Sep 2025.
Copyright: © 2025 Wang, Liu, Lu, Xi, Feng, Ma, Lyu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jian Lyu, drjianlyu@foxmail.com
Yanming Xie, ktzu2018@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.